Personal Information

  • Pharmacology and toxicology
  • Neuropharmacology
  • Preclinical drug discovery
  • Cellular and molecular biology
  • Neurological disorders
  • Huntington’s Disease
  • Parkinson’s Disease
  • M.Pharm. Semester I
  • MPL101T Modern Pharmaceutical Analytical Techniques
  • MPL102T Advanced Pharmacology -I
  • MPL103T Pharmacological and Toxicological Screening Methods - I
  • MPL104T Cellular and Molecular Pharmacology
  • MPL05P   Pharmacology Practical -I
  • MPL106S Seminar/Assignment

Research

  • Senior Research Fellowship (SRF) awarded by Indian Council of Medical Research (ICMR), for the project entitled “Neuropharmacological investigation on raloxifene and fulvestrant against haloperidol-induced animal model of Tardive Dyskinesia: Possible role of GPR30 receptor”

 

Animal Model Validated & Developed

  • Haloperidol-Induced Tardive Dyskinesia model in Adult Wistar Rats and in Zebrafish
  • 3-Nitropropionic acid (3-NP) induced Huntington’s disease in adult zebrafish.
  • Mercury-Induced Amyotrophic Lateral Sclerosis in Adult Wistar Rats
  • Ethidium Bromide Induced Multiple Sclerosis Model in Adult Wistar Rats

 

Target explored in neurological disorders

GPER1/GPR30, PI3k/Akt, Nrf2/HO-1, GSK-3β, c-JNK/p38MAPK

Drug Induced Movement Disorder

  • Raloxifene and Fulvestrant Exert Antioxidant, Anti-Inflammatory, and Antiapoptotic Action Against Haloperidol-Induced Tardive Dyskinesia in Rats via Activation of the GPER1/PI3k/Akt/Nrf2/HO-1 Signaling Pathways. Journal of biochemical and molecular toxicology, 39(8), e70413.

 

  • G-Protein-Coupled Estrogen Receptor 1 (GPER1) Activation Mitigates Haloperidol-Induced Neurotoxicity in SHSY-5Y Cells and Improves Motor Functions in Adult Zebrafish. Neurochemical research, 50(2), 119.

 

  • Glycyrrhizic Acid Mitigates Haloperidol-Induced Neurotoxicity in SHSY-5Y Cells and Rats Via Activation of PI3k/Akt/Nrf2 Pathways. Neurochemical Research, 50(1), 1-19.

 

  • Bacillus Calmette–Guérin Vaccine Attenuates Haloperidol-Induced TD-like Behavioral and Neurochemical Alteration in Experimental Rats." Biomolecules 13, no. 11 (2023): 1667.

 

Huntington’s Disease and Parkinson’s Disease

 

  • Auranofin-loaded chitosan-lipid hybrid nanoparticle protects against the in-vitro/in-vivo model of Parkinson’s disease via modulation of GSK-3β/Nrf2/HO-1 signaling. European Journal of Pharmacology, 177523.

 

  • Elucidating the neuroprotective potential of arbutin in 3-NPA induced HD-like pathology: Insights from in silico, in vitro, and in vivo models. Behavioural Brain Research, 483, 115475.

 

Multiple Sclerosis

 

  • Nrf2/HO-1 Signaling Stimulation through Acetyl-11-Keto-Beta-Boswellic Acid (AKBA) Provides Neuroprotection in Ethidium Bromide-Induced Experimental Model of Multiple Sclerosis." Genes 13, no. 8 (2022): 1324

 

  • Neuroprotection by solanesol against ethidium bromide-induced multiple sclerosis-like neurobehavioral, molecular, and neurochemical alterations in experimental rats, Phytomedicine Plus, Volume 1, Issue 4, 2021,100051

 

  • Inhibition of c-JNK/p38MAPK signaling pathway by Apigenin prevents neurobehavioral and neurochemical defects in ethidium bromide-induced experimental model of multiple sclerosis in rats: Evidence from CSF, blood plasma and brain samples. Phytomedicine Plus 1, no. 4 (2021): 100139.

 

Alzheimer’s Disease

  • In vitro and in vivo investigations of chromone derivatives as potential multitarget-directed ligands: Cognitive amelioration utilizing a scopolamine-induced zebrafish model. ACS Chemical Neuroscience, 15(14), 2565-2585.
  • ML-based prediction to experimental validation: Development of dihydroquinazoline based multi-potent ligands as anti-Alzheimer's agents. Computers in Biology and Medicine, 196, 110762.

 

Title Attachment File Other Link
PDF icon Dr. Shubham Upadhayay C.V.pdf